{
    "root": "69d11d5f-adf1-142a-b4e2-1bace590eba8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fluoxetine hydrochloride",
    "value": "20250520",
    "ingredients": [
        {
            "name": "Fluoxetine hydrochloride",
            "code": "I9W7N6B1KJ"
        },
        {
            "name": "ferrosoferric oxide",
            "code": "XM0M87F357"
        },
        {
            "name": "povidone",
            "code": "FZ989GH94E"
        },
        {
            "name": "gelatin",
            "code": "2G86QN327L"
        },
        {
            "name": "glycine",
            "code": "TE7660XO1C"
        },
        {
            "name": "hypromelloses",
            "code": "3NXW29V3WO"
        },
        {
            "name": "HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)",
            "code": "87Y6436BKR"
        },
        {
            "name": "isopropyl alcohol",
            "code": "ND2M416302"
        },
        {
            "name": "methylene chloride",
            "code": "588X2YUY0A"
        },
        {
            "name": "ferric oxide red",
            "code": "1K09F3G675"
        },
        {
            "name": "raw sugar",
            "code": "8M707QY5GH"
        },
        {
            "name": "talc",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "titanium dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "triethyl citrate",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "ferric oxide yellow",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "fluoxetine delayed-release capsules indicated treatment : • acute maintenance treatment major depressive disorder [ ( 14.1 ) ] .",
    "contraindications": "indication adult pediatric mdd ( 2.1 ) 20 mg/day ( initial dose ) 10 20 mg/day ( initial dose ) lower less frequent used patients hepatic impairment , elderly , patients concurrent disease multiple concomitant medications ( 2.7 ) dosing fluoxetine weekly capsules - initiate 7 days last daily dose fluoxetine 20 mg ( 2.1 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "serotonin syndrome maois : maois intended treat psychiatric disorders fluoxetine within 5 weeks stopping treatment fluoxetine . fluoxetine within 14 days stopping maoi intended treat psychiatric disorders . addition , start fluoxetine patient treated linezolid intravenous methylene blue ( 4.1 ) pimozide : . risk qt prolongation interaction ( 4.2 , 5.11 , 7.7 , 7.8 ) thioridazine : . risk qt interval prolongation elevated thioridazine plasma levels . thioridazine within 5 weeks discontinuing fluoxetine . thioridazine within 5 weeks discontinuing fluoxetine ( 4.2 , 5.11 , 7.7 , 7.8 )",
    "indications_original": "Fluoxetine delayed-release capsules are indicated for the treatment of:\n                  • Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1)].",
    "contraindications_original": "Indication Adult Pediatric MDD (2.1) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7) Dosing with fluoxetine weekly capsules - initiate 7 days after the last daily dose of fluoxetine 20 mg ( 2.1 )",
    "adverseReactions_original": "Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine. Do not use fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start fluoxetine in a patient who is being treated with linezolid or intravenous methylene blue (4.1) Pimozide: Do not use. Risk of QT prolongation and drug interaction ( 4.2 , 5.11 , 7.7 , 7.8 ) Thioridazine: Do not use. Risk of QT interval prolongation and elevated thioridazine plasma levels. Do not use thioridazine within 5 weeks of discontinuing fluoxetine. Do not use thioridazine within 5 weeks of discontinuing fluoxetine ( 4.2 , 5.11 , 7.7 , 7.8 )"
}